Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his spare time in his backyard, sketching out designs for new ...

Twelve months after releasing a roadmap to shift away from animal testing requirements, the FDA has declared mission ...

Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to ...

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy ...

After a recent streak of buyouts by some of Big Pharma's serial acquirers, Belgium's UCB is getting | The agreement fulfills ...

The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...

Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its ...

The FDA’s former top drug regulator Richard Pazdur, M.D., has lamented the loss of expert voices at the agency. | Asked by ...

Aligos Therapeutics has secured a $25 million cash infusion in return for selling the China rights to its phase 2-stage ...

The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 ...

After its bet on a rare eye disease gene therapy ended in a phase 3 fail last year, Johnson & Johnson is now returning the ...

To Ocugen CEO Shankar Musunuri, Ph.D., most gene therapy biotechs today lack vision. | Many gene therapy outfits focus on ...